GSK’s Blenrep Hit By Trial Failure, Raising Questions About Its Future In The Myeloma Market

Phase III Study Misses Endpoint

The DREAMM-3 study was meant to be a confirmatory study for Blenrep, and its failure raises concerns over its use in earlier lines of therapy and the possibility that it could be removed from the market.

DREAMM-3's failure does not bode well for further readouts in earlier myeloma therapy, and could even see Blenrep removed from the market. • Source: GSK

GSK’s efforts to build a presence in the multiple myeloma market with Blenrep (belantamab mafodotin) have suffered a major setback, after it failed to improve on standard second-line therapy in a confirmatory Phase III study.

The BCMA-targeted antibody-drug conjugate failed to meet its primary endpoint of improved progression-free survival (PFS) compared with Celgene’s Pomalyst...